Evolving role of systemic inflammation in comorbidities of chronic obstructive pulmonary disease

Chinese Medical Journal

Volumn 123, Issue 23, 2010, Pages 3467-3478

  Wang, Zeng Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Comorbidities; Systemic inflammation

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; PREDNISONE; SALMETEROL;

AIRWAY OBSTRUCTION; ANXIETY; ARTERIAL STIFFNESS; ARTICLE; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FRAGILITY FRACTURE; HEART ARRHYTHMIA; HEART DISEASE; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LIFE EXPECTANCY; LUNG CANCER; LUNG EMBOLISM; LUNG EMPHYSEMA; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PEPTIC ULCER; PNEUMONIA; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SIDE EFFECT; SLEEP APNEA SYNDROME; SMOKING; SMOKING CESSATION; SOCIAL STATUS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

ANXIETY; CARDIOVASCULAR DISEASES; COMORBIDITY; DEPRESSION; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASES; OSTEOPOROSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMBOLISM; SMOKING;

EID: 78649885309     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.23.017     Document Type: Article

References (97)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007; 176: 532-555.
2. MacNee W, Tuder RM. New paradigms in the pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6: 527-531.
3. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-799.
4. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
5. Zhong N, Wang C, Yao W, Chen R, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China. Am J Respir Crit Care Med 2007; 176: 753-760.
6. Zhou Y, Wang C, Yao W, Chen P, Kang J, Huang S, et al. COPD in Chinese nonsmokers. Eur Respir J 2009; 33: 509-518.
7. Minnino DM, Watt G, Hole D. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-643.
8. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007; 131: 1557-1566.
9. Agusti A. Thomas a. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006; 3: 478-481.
10. Fabbri LM, Boschetto P, Mapp CE. COPD guidelines: the important thing is not to stop questioning. Am J Respir Crit Care Med 2007; 176: 527-528.
11. Horton R. The neglected epidemic of chronic disease. Lancet 2005; 120: 437-447.
12. Lopez AD, Mathers CD, Ezzati M, Jamison DJ, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
13. Epping-Jordan JE, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases taking stepwise action. Lancet 2005; 366: 1667-1671.
14. Charlson M, Charlson RE, Briggs W, Hollenberg J. Can disease management target patient most likely to generate high cost? The impact of comorbidity. J Gen Intern Med 2007; 22: 464-469.
15. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbidity diseases: implication for pay for performance. JAMA 2005; 294: 716-724.
16. Luppi F, Franco F, Beghe B, Fabbri LM. Treatment of chronic obstructive pulmonary disease and its co morbidities. Proc Am Thorac Soc 2008; 5: 848-856.
17. Rodriguez-Roisim R, Soriano JB. Chronic obstructive pulmonary disease with lung cancer and lorcardiovascular disease. Proc Am Thorac Soc 2008; 5: 842-847.
18. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487-497.
19. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26-33.
20. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
21. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 549-555.
22. van Manen JG, Bindels PJ, Ijermans CJ, Vander Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001; 54: 289-293.
23. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 2000; 160: 2653-2658.
24. van Weel C, Schellevis FG. Comorbidity and guidelines: conflicting interests. Lancet 2006; 367: 550-551.
25. Anthonison NR, Connett JE, Enright PL, Mantreda J; Lung Health Study Research Group. Hospitalization and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
26. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-2011.
27. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
28. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease. Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70.
29. Kinnunen T, Saynajakangas O, Tuuponen T, Keistinen T, Impact of comorbidities on the duration of COPD patients' hospital episodes. Respir Med 2003; 97: 143-146.
30. Jamal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259.
31. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respire J 2006; 28: 1245-1257.
32. Mannino DM, Brown C, Giovino GA, Obstructive lung disease death in the United States from 1979 through 1993. An analysis using multiple cause mortality data. Am J Respir Crit Care Med 1997; 156: 814-818.
33. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640-2646.
34. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary Disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 2006; 7: 70-78.
35. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-415.
36. Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J 2006; 28: 781-785.
37. Sorino JB, Sauleda J. How the COPD patients should be assessed for comorbidities. In: Rennard SI, Rodriguez-roisin R, Huchon G, Roche N, eds. Clinical management of chronic obstructive pulmonary disease, 2nd ed. New York: Informa Healthcare; 2007: 211-238.
38. van Manen JG, Bindels PJ, Dekker Ew, Ijzermans CJ, Bottema BJ, van der Zee JS, et al. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med 2001; 95: 496-504.
39. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
40. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
41. Zvezdin B, Milutinov S, Kojicic M, Hadnajev M, Hromis S, Markovic M, et al. A post mortem analysis of major cause of early death in patients hospitalized with chronic obstructive pulmonary disease. Chest 2009; 136: 376-380.
42. Sin DD. Is COPD really a cardiovascular disease? Chest 2009; 136: 329-330.
43. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
44. Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 543-548.
45. Vivodtzev I, Lacasse Y. Stimulating advance in chronic heart failure and COPD. Chest 2009; 136: 5-6.
46. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006; 8: 706-711.
47. Rutten FH, Cramer MJ, Zuitheff NP, Lammers JW, Verveij W, Grobbee DE, et al. Comparison of B-type natriuretic peptide assays for identifying heart in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2009; 9: 651-659.
48. Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008; 63: 306-311.
49. Vivodtzer L, Minet C, Wuyam B, Borel JC, Vottero G, Monneret D, et al. Significant improvement in arterial stiffness after endurance training in patients with COPD. Chest 2010; 137: 585-592.
50. Rutschmann OT, Cornuz J, Poletti PA, Bridevaux PO, Hugli OW, Qanadli SD, et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 2007; 62: 121-125.
51. Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodrigurz-Roisin R, et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632-688.
52. Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD. Chest 2008; 134: 808-814.
53. Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and meta-analysis. Chest 2009; 135: 786-793.
54. Monreal M, Munoz-Torrero JF, Naraine VS, Jimenez D, Soler S, Rabunal R, et al. RIETE Investigators. Pulmonary embolism in patients with chronic obstructive pulmonary disease of congestive heart failure. Am J Med 2006, 119: 851-858.
55. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55: 1000-1006.
56. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status and quality of life. Arch Intern Med 2007; 167: 60-67.
57. Norwood R. Prevalence and impact of depression in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2006; 12: 113-117.
58. Schneider C, Jick SS, Bothner U, Meier CR. COPD and the risk of depression. Chest 2010; 137: 341-347.
59. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 2008; 178: 911-920.
60. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding unanswered questions, and research needs. Chest 2008; 134 (4 Suppl): 43S-56S.
61. Felker B, Katon W, Hedrick SC, Rasmussen J, McDonnell MB, Fihn SD. The association between depressive symptoms and health status in patients with chronic pulmonary disease. Gen Hosp Psychiatry 2001; 23: 56-61.
62. Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, et al. Sex, depression and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 2007; 167: 2345-2353.
63. van den Bemt L, Schermer T, Bor H, Smink R, van Weel-Baumgarten, Lucassen P, et al. The risk for depression comorbidity in patients with COPD. Chest 2009; 135: 108-114.
64. Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Cirt Care Med 2009; 180: 134-137.
65. Jorgensen NR, Schwarz P. Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2008; 14: 122-127.
66. Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systemic review. Eur Respir J 2009; 34: 209-218.
67. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007; 101: 177-185.
68. Carter JD, Patel S, Sultan FL, Thompson ZJ, Margaux H, Sterrett A, et al. The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 2008; 102: 1165-1172.
69. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, et al. Prevalence and progression of osteoporosis in patients with COPD. Results from the Towards a Revolution in COPD Health Study. Chest 2009; 136: 1456-1465.
70. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008; 134: 1244-1249.
71. Agusti A, Soriano JB. COPD as a systemic disease. COPD 2008; 5: 133-138.
72. Gosker HR, Kubat B, Schaart G, van der Vasse GJ, Wouters EF, Schols AM. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 280-285.
73. Montes de Oca M, Torres SH, Gonzalez Y. Peripheral muscle composition and health status in patients with COPD. Respir Med 2006; 100: 1800-1806.
74. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007; 62: 115-120.
75. Gosker HR, Engelen MP, van Mameren H, van Dijk PJ, van der Vusse GJ, Wouters EF, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002; 76: 113-119.
76. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
77. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
78. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, et al. Chronic obstructive pulmonary disease, asthma and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478-2484.
79. Manson JE, Ajani UA, Liu S, Nathan DM, Hennekens CH. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med 2000; 109: 538-542.
80. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284-290.
81. Ucgun I, Oztuna F, Dagli CE, Yildirim H. Relationship of metabolic alkalosis, azotemia and morbidity in patients with chronic obstructive pulmonary disease and hypercapnia. Respiration 2008; 76: 270-278.
82. Villablanca AC, McDonald JM, Rutledge JC. Smoking and cardiovascular disease. Clin Chest Med 2000; 21: 159-172.
83. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest 2009; 136: 734-743.
84. Marquis K, Maltais F, Duguay V, Bezeau AM, LeBlanc P, Jobin J, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005; 25: 226-232; discussion 233-234.
85. Lee HM, Chung SJ, Lopez VA, Wong ND. Association of FVC and total mortality in US adults with metabolic syndrome and diabetes. Chest 2009; 136: 171-176.
86. van Gestel YR, Hoeks SE, Sin DD, Hüzeir V, Stam H, Mertens FW, et al. COPD and cancer mortality: the influence of statins. Thorax 2009; 64: 963-967.
87. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kann RE, Connett JE. The effects of a smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
88. Zhang H. Molecular signaling and genetic pathways of senescence: its role in tumorigenesis and aging. J Cell Physiol 2007; 210: 567-574.
89. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey Follow-up. Arch Intern Med 2003; 163: 1475-1480.
90. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004; 59: 679-681.
91. Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, et al. Decline in NRF2-regulated antioxidants in COPD lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 2008; 178: 592-604.
92. Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc 2009; 6: 532-534.
93. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101: 2139-2144.
94. Lieberman D, Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, et al. Pneumonic vs. nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 1264-1270.
95. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PN, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-782.
96. Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010; 35: 1209-1205.
97. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med 2009; 180: 692-700.